Advertisement


Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

David A. Hyman, MD, JD, on Inclusive Shared Savings

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Advertisement